FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006142779> ?p ?o ?g. }

• W2006142779 endingPage "195" @default.
• W2006142779 startingPage "189" @default.
• W2006142779 abstract "We studied the clinical course of 59 lupus patients with end-stage renal disease (ESRD) to determine their longterm prognosis and delineate the evolution of their lupus activity. The study population was predominantly female (86%) and young (mean age, 27.4 years), and they were observed for a mean of 6.5 years from the inception of dialysis. At the time dialysis was initiated, only 21 patients (35.6%) had clinically active systemic lupus erythematosus (SLE). The remaining patients progressed to ESRD despite the absence of clinical lupus activity. Lupus activity was clinically apparent in 55.4% of patients in the first year, 6.5% in the fifth, and none in the tenth year. In 45% of patients, lupus activity was clinically inactive at entry to ESRD and remained inactive throughout the observation period. Serological activity declined proportionally, but to a lesser extent than clinical activity. Cumulative patient survival was 81.1% and 74.6% at the fifth and tenth year, respectively, from the inception of dialysis treatment; similarly it was 78% at the fifth and tenth year after the transplantation. Graft survival was 60.4% at the fifth and 45.5% at the tenth year. No one had recurrence of clinical lupus nephritis in the graft for up to 16 years of follow-up. Fourteen patients died from either infectious or cardiovascular complications, but none from SLE per se. This long-term study with a large number of lupus patients confirms our previous findings that the progression of renal disease to ESRD may be mediated by nonimmunologic mechanisms, as well as immunologic insults. Most patients, regardless of the mode of treatment for ESRD, remain clinically quiescent for lupus activity despite persistent serological abnormalities. Patient survival, either on dialysis treatment or with a kidney transplant, is comparable to that of the general dialysis population. We conclude that in lupus patients with ESRD, regression of serological and clinical expression of SLE is continuous over time. Progressive resolution of lupus activity permits judicious withdrawal of immunosuppressive therapy, as well as a favorable long-term outcome of the patient. We studied the clinical course of 59 lupus patients with end-stage renal disease (ESRD) to determine their longterm prognosis and delineate the evolution of their lupus activity. The study population was predominantly female (86%) and young (mean age, 27.4 years), and they were observed for a mean of 6.5 years from the inception of dialysis. At the time dialysis was initiated, only 21 patients (35.6%) had clinically active systemic lupus erythematosus (SLE). The remaining patients progressed to ESRD despite the absence of clinical lupus activity. Lupus activity was clinically apparent in 55.4% of patients in the first year, 6.5% in the fifth, and none in the tenth year. In 45% of patients, lupus activity was clinically inactive at entry to ESRD and remained inactive throughout the observation period. Serological activity declined proportionally, but to a lesser extent than clinical activity. Cumulative patient survival was 81.1% and 74.6% at the fifth and tenth year, respectively, from the inception of dialysis treatment; similarly it was 78% at the fifth and tenth year after the transplantation. Graft survival was 60.4% at the fifth and 45.5% at the tenth year. No one had recurrence of clinical lupus nephritis in the graft for up to 16 years of follow-up. Fourteen patients died from either infectious or cardiovascular complications, but none from SLE per se. This long-term study with a large number of lupus patients confirms our previous findings that the progression of renal disease to ESRD may be mediated by nonimmunologic mechanisms, as well as immunologic insults. Most patients, regardless of the mode of treatment for ESRD, remain clinically quiescent for lupus activity despite persistent serological abnormalities. Patient survival, either on dialysis treatment or with a kidney transplant, is comparable to that of the general dialysis population. We conclude that in lupus patients with ESRD, regression of serological and clinical expression of SLE is continuous over time. Progressive resolution of lupus activity permits judicious withdrawal of immunosuppressive therapy, as well as a favorable long-term outcome of the patient." @default.
• W2006142779 created "2016-06-24" @default.
• W2006142779 creator A5009554990 @default.
• W2006142779 creator A5018907838 @default.
• W2006142779 creator A5021481034 @default.
• W2006142779 creator A5032456155 @default.
• W2006142779 creator A5060505506 @default.
• W2006142779 creator A5063040277 @default.
• W2006142779 creator A5067430398 @default.
• W2006142779 creator A5078821163 @default.
• W2006142779 date "1990-09-01" @default.
• W2006142779 modified "2023-10-14" @default.
• W2006142779 title "Systemic Lupus Erythematosus in Patients with End-Stage Renal Disease: Long-Term Follow-Up on the Prognosis of Patients and the Evolution of Lupus Activity" @default.
• W2006142779 cites W1972432613 @default.
• W2006142779 cites W1993182363 @default.
• W2006142779 cites W1997112535 @default.
• W2006142779 cites W1999387122 @default.
• W2006142779 cites W2002895225 @default.
• W2006142779 cites W2003730630 @default.
• W2006142779 cites W2004632147 @default.
• W2006142779 cites W2011423819 @default.
• W2006142779 cites W2015695597 @default.
• W2006142779 cites W2018154805 @default.
• W2006142779 cites W2032907616 @default.
• W2006142779 cites W2045132089 @default.
• W2006142779 cites W2053600181 @default.
• W2006142779 cites W2088779243 @default.
• W2006142779 cites W2104638089 @default.
• W2006142779 cites W2122267500 @default.
• W2006142779 cites W2146203649 @default.
• W2006142779 cites W2318522292 @default.
• W2006142779 cites W2325870812 @default.
• W2006142779 cites W2332578109 @default.
• W2006142779 cites W2336821934 @default.
• W2006142779 cites W2408148257 @default.
• W2006142779 cites W2470754578 @default.
• W2006142779 cites W4235733682 @default.
• W2006142779 doi "https://doi.org/10.1016/s0272-6386(12)81017-1" @default.
• W2006142779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2399912" @default.
• W2006142779 hasPublicationYear "1990" @default.
• W2006142779 type Work @default.
• W2006142779 sameAs 2006142779 @default.
• W2006142779 citedByCount "76" @default.
• W2006142779 countsByYear W20061427792012 @default.
• W2006142779 countsByYear W20061427792013 @default.
• W2006142779 countsByYear W20061427792014 @default.
• W2006142779 countsByYear W20061427792015 @default.
• W2006142779 countsByYear W20061427792016 @default.
• W2006142779 countsByYear W20061427792018 @default.
• W2006142779 countsByYear W20061427792019 @default.
• W2006142779 countsByYear W20061427792020 @default.
• W2006142779 countsByYear W20061427792021 @default.
• W2006142779 countsByYear W20061427792022 @default.
• W2006142779 countsByYear W20061427792023 @default.
• W2006142779 crossrefType "journal-article" @default.
• W2006142779 hasAuthorship W2006142779A5009554990 @default.
• W2006142779 hasAuthorship W2006142779A5018907838 @default.
• W2006142779 hasAuthorship W2006142779A5021481034 @default.
• W2006142779 hasAuthorship W2006142779A5032456155 @default.
• W2006142779 hasAuthorship W2006142779A5060505506 @default.
• W2006142779 hasAuthorship W2006142779A5063040277 @default.
• W2006142779 hasAuthorship W2006142779A5067430398 @default.
• W2006142779 hasAuthorship W2006142779A5078821163 @default.
• W2006142779 hasConcept C126322002 @default.
• W2006142779 hasConcept C159654299 @default.
• W2006142779 hasConcept C203014093 @default.
• W2006142779 hasConcept C2775915377 @default.
• W2006142779 hasConcept C2776912625 @default.
• W2006142779 hasConcept C2778063415 @default.
• W2006142779 hasConcept C2779134260 @default.
• W2006142779 hasConcept C2779912601 @default.
• W2006142779 hasConcept C2779978075 @default.
• W2006142779 hasConcept C2908647359 @default.
• W2006142779 hasConcept C3019040382 @default.
• W2006142779 hasConcept C71924100 @default.
• W2006142779 hasConcept C90924648 @default.
• W2006142779 hasConcept C99454951 @default.
• W2006142779 hasConceptScore W2006142779C126322002 @default.
• W2006142779 hasConceptScore W2006142779C159654299 @default.
• W2006142779 hasConceptScore W2006142779C203014093 @default.
• W2006142779 hasConceptScore W2006142779C2775915377 @default.
• W2006142779 hasConceptScore W2006142779C2776912625 @default.
• W2006142779 hasConceptScore W2006142779C2778063415 @default.
• W2006142779 hasConceptScore W2006142779C2779134260 @default.
• W2006142779 hasConceptScore W2006142779C2779912601 @default.
• W2006142779 hasConceptScore W2006142779C2779978075 @default.
• W2006142779 hasConceptScore W2006142779C2908647359 @default.
• W2006142779 hasConceptScore W2006142779C3019040382 @default.
• W2006142779 hasConceptScore W2006142779C71924100 @default.
• W2006142779 hasConceptScore W2006142779C90924648 @default.
• W2006142779 hasConceptScore W2006142779C99454951 @default.
• W2006142779 hasIssue "3" @default.
• W2006142779 hasLocation W20061427791 @default.
• W2006142779 hasLocation W20061427792 @default.
• W2006142779 hasOpenAccess W2006142779 @default.
• W2006142779 hasPrimaryLocation W20061427791 @default.
• W2006142779 hasRelatedWork W2007820849 @default.
• W2006142779 hasRelatedWork W2027893008 @default.

• next